|
||
Report |
Correspondence to Michelle E. King: mk2j{at}virginia.edu; or George S. Bloom: gsb4g{at}virginia.edu
|
|
|---|
| Introduction |
|---|
|
|
|---|
A promising new focus of investigation has been the role that nonfibrillar forms of Aß, and to a lesser extent tau, play in AD. Soluble forms of Aß are more potent than fibrillar forms at eliciting cellular responses, such as increased apoptosis (Sponne et al., 2003) and decreased synaptic plasticity (Walsh et al., 2002). In fact, studies of transgenic animal models and AD patients have shown that cognitive deficits and synaptic loss correlate with soluble Aß, rather than senile plaques (Kayed et al., 2003; Oddo et al., 2006), suggesting that AD is initiated well before extracellular Aß deposits are evident.
Neuronal microtubules serve as highways for axonal transport and, by extension, are critically involved in supporting synaptic integrity and neuronal viability. The loss of axonal microtubules is a hallmark of AD, and a longstanding question has been whether their loss or the accumulation of insoluble tau filaments and Aß plaques causes neurodegeneration. To shed light on this issue, we have used cultured neuronal and nonneuronal cells to model effects of various forms of Aß on microtubules. Remarkably, we found that brief exposure of cells to submicromolar levels of prefibrillar Aß42 caused massive and rapid tau-dependent disassembly of microtubules. Similar results were obtained for prefibrillar Aß40, albeit at much higher concentrations, but microtubules in either tau-expressing or -deficient cells were relatively resistant to fibrillar Aß. Collectively, these results highlight the most dramatic, rapid, and sensitive link between Aß and tau described to date, identify microtubules as primary, tau-dependent targets of Aß, and suggest that nonfibrillar Aß and tau underlie the detrimental neurodegeneration observed in AD before the accumulation of fibrillar forms in senile plaques and neurofibrillary tangles.
| Results and discussion |
|---|
|
|
|---|
|
|
Tau was found to be required for microtubule disassembly in primary hippocampal neurons induced by prefibrillar Aß42. Neurons were treated with siRNA to reduce tau expression to trace levels (Fig. 2 D and Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.200605187/DC1). After 2 h of exposure to 2 µM prefibrillar Aß42, the level of polymerized tubulin remained nearly unchanged in tau-deficient neurons (
20% soluble tubulin), whereas the tau-expressing neurons again showed an increase in soluble tubulin (
60% soluble tubulin). It was not possible to determine how much tau was microtubule bound or soluble in these experiments, because the tau was quantitatively solubilized by the Triton X-100 under conditions in which the polymerized tubulin was resistant to extraction (Black et al., 1996). Thus, the results for tubulin demonstrate that the endogenous tau in neurons, like transfected tau in CV-1 cells, makes microtubules acutely sensitive to prefibrillar Aß42.
Treatment of tau-expressing neurons with prefibrillar Aß42 under conditions that induced microtubule disassembly did not cause increased AD-like tau phosphorylation at any of several sites (Fig. 3). This was found by immunoblotting using phosphorylation-sensitive monoclonal anti-tau antibodies: PHF-1, AT180, and tau-1. Although many additional AD-like phosphorylation sites remain to be examined, these data suggest that conversion of tau to an AD-like phosphorylation state does not underlie the release of tau from microtubules and subsequent microtubule disassembly induced by prefibrillar Aß42.
|
70% identical to that of tau's (Dehmelt and Halpain, 2005). 3 h of exposure to prefibrillar Aß42 did not cause any apparent loss of microtubule integrity in cells. A region of tau responsible for conferring sensitivity to Aß42 was mapped using a combination of tau/MAP2c chimeric proteins and a CFP-tagged tau fragment. Only cells expressing "tau chimera," a GFP-tagged protein comprising the microtubule binding domain of MAP2c flanked by the N-terminal arm and C-terminal tail of tau (Fig. 4 B and Videos 57, available at http://www.jcb.org/cgi/content/full/jcb.200605187/DC1) responded to the addition of prefibrillar Aß42.
Similar activity was observed when the tau projection domain-CFP, which did not localize on microtubules, was expressed in cells that subsequently were treated with prefibrillar Aß42 (Fig. 4 B and Video 8). The qualitative results shown in Fig. 4 and Videos 1 and 48 were confirmed by quantitation of fluorescence micrographs for microtubule-containing cells before and after 3 h of exposure to prefibrillar Aß42 (Fig. 5).
The N-terminal half of tau therefore responds to prefibrillar Aß42 and does not have to target to microtubules to exert its effects. Furthermore, the closely related neuronal microtubule protein, MAP2c, cannot substitute for tau at promoting microtubule disassembly in cells exposed to prefibrillar Aß42.
|
|
That the combination of prefibrillar Aß and nonfilamentous tau were able to elicit such a dramatic disruption of microtubules supports the hypothesis that fibrillar forms of tau and Aß are at least somewhat neuro-protective, because they sequester more dangerous, nonfibrillar forms of Aß and tau (Tanzi, 2005). The fact that tau is required for Aß-induced microtubule loss could explain, at least in part, why neurons, the principal tau-expressing cell type, are the cellular targets for destruction in AD. Moreover, the model presented here does not preclude other toxic functions of prefibrillar or fibrillar Aß or filamentous tau, such as tau-dependent degeneration of cultured neurons induced by fibrillar Aß40 (Rapoport et al., 2002) or toxicity related to intracellular tau filament accumulation (Khlistunova et al., 2006). Nevertheless, the rapid, tau-dependent destruction of microtubules that we observed to be induced by submicromolar concentrations of prefibrillar Aß42 suggests that this process is one of the seminal events in AD pathogenesis at the cellular level.
| Materials and methods |
|---|
|
|
|---|
-tubulin (Sigma-Aldrich), C4 anti-actin (Chemicon), 6E10 anti-Aß (Signet; recognizes all forms of Aß40 and Aß42), fluorescently tagged goat antimouse IgG and goat antirabbit (Southern Biotechnology Associates, Inc.) and HRP-labeled goat antimouse IgG (KPL) were acquired from the indicated commercial sources. I-11 is one of the Glabe laboratory's rabbit polyclonal antibodies against oligomeric Aß (Kayed et al., 2003).
Cell culture
CV-1 (African green monkey kidney) cells were cultured in DME (Invitrogen) supplemented with 10% Cosmic Calf Serum (Hyclone) and 50 µg/ml gentamycin. Cells were transiently transfected using Fugene (Roche) or a nucleofector (Amaxa) with cDNAs for the longest human isoform of tau or the projection domain (amino acids 1248) of tau linked at their C terminals to ECFP or EYFP (CLONTECH Laboratories, Inc.); with YFP
-tubulin (CLONTECH Laboratories, Inc.); or with MAP2c or MAP2c/tau chimeras (Roger et al., 2004) tagged at their N termini with GFP, which were gifts from S. Halpain (The Scripps Research Institute, La Jolla, CA). For nucleofection, program A-033 and solution V were used according to the manufacturer's instructions. Primary cortical neurons were purchased from Genlantis and cultured according to their guidelines. Primary hippocampal neurons (Wisco et al., 2003) were grown for at least 8 d before Aß treatment. The tau siRNA (SMARTpool; Dharmacon) and control scrambled siRNA (Nonspecific duplex II; Dharmacon) were transfected into primary hippocampal neurons by nucleofection using the rat neuron solution (Amaxa) and program G-13 (Qiang et al., 2006). Cells were cultured for 4 d after nucleofection and were then exposed to Aß.
Aß treatment
Previously described methods were used to synthesize (Burdick et al., 1992) and resuspend (Kayed et al., 2003) Aß42 and Aß40. The Aß was added to cells cultured in serum-free DME to final concentrations from 0.1 to 5 µM. Prefibrillar Aß was used in the first and second days after resuspension, whereas fibrillar Aß was used after at least 7 d of stirring.
Microscopy
Live cell imaging and immunofluorescence microscopy were performed as previously described (Mateer et al., 2002) on an Axiovert 100 (Carl Zeiss MicroImaging, Inc.) equipped with 63x 1.4 NA planapo and 25x 0.8 NA plan-neofluar objectives (Carl Zeiss MicroImaging, Inc.), a CARV spinning disk confocal head (BD Biosciences), an X-Cite 120 illuminator (EXFO Photonic Solutions), a cooled charge-coupled device (Orca ER; Hamamatsu), and OpenLab software (Improvision) for image acquisition and processing. For live cell time-lapse imaging, the cells were maintained on the microscope stage in DME at 37°C in an atmosphere of 95% air and 5% CO2. The supplemental time-lapse videos were produced by first using the public domain software, ImageJ to pseudocolor eight-bit grayscale images stacks to eight-bit cyan, green, or yellow image stacks, and then using QuickTime Pro 7 and Keynote 3 (Apple) to produce self-playing videos compressed with the H.264 codec. For electron microscopy, primary cortical and hippocampal neurons were grown on glass coverslips, treated with Aß42, and fixed in 2.5% glutaraldehyde plus 0.5% tannic acid in 0.1 M cacodylate buffer, pH 7.4. Cells on coverslips were dehydrated and capsule embedded in EPON, and the glass coverslip was removed from the EPON by alternating liquid nitrogen and warm water submersion of the capsule. Sectioned samples were viewed on an electron microscope (JEM 1010; JEOL) at 80 kV, and images were captured using a 16-megapixel cooled charge-coupled device (SAI-12c; Scientific Instruments and Applications, Inc).
Quantitation of fluorescence micrographs
Nucleofection was used to express fusion proteins of CFP, GFP, or YFP coupled to tau, the N-terminal tau arm, MAP2c, or MAP2c/tau chimeras in CV-1 cells growing on glass coverslips. Cultures that either were or were not exposed to prefibrillar or fibrillar Aß42 for 3 h were fixed and permeabilized for 5 min in 20°C methanol and stained for immunofluorescence with anti
-tubulin followed by TRITC-labeled goat antimouse IgG. For each coverslip, six randomly chosen fields of view were photographed separately in both the TRITC channel and the CFP, GFP, or YFP channel using the 25x objective. Typically, 4050% of the total cells expressed the transfected protein. Next, without knowing the identity of the sample, an observer counted the total cells and microtubule-containing cells in one anti-tubulin field and then counted the total number of transfected cells and microtubule-containing transfected cells in the same field. This process was repeated for the remaining fields of the coverslip, and the results from all six fields, which comprised
500 total cells, were merged into a single dataset. Each such experiment was performed in triplicate, and the net results were graphed in Figs. 1 E and 5 as the mean ± SD of the percentage of microtubule-containing transfected and nontransfected cells for each experimental condition. For Fig. 5, pairwise comparisons were made of transfected versus nontransfected cells at 0 and 3 h of Aß exposure and of nontransfected cells at 0 versus 3 h of Aß exposure.
Biochemical quantitation of unassembled and polymerized tubulin
CV-1 cells and primary hippocampal neurons were treated with 13 µM prefibrillar or fibrillar Aß42. Cells were washed briefly with PBS and extracted with PHEM buffer (60 mM Pipes, pH 6.9, 25 mM Hepes, 10 mM EGTA, and 2 mM MgCl2) with 10 µM taxol and 0.2% Triton X-100 for 5 min. The buffer was collected and centrifuged for 5 min at maximum speed in a table top centrifuge (model 5415; Eppendorf), and the supernatant was removed and mixed with 1/5 volume of 6x sample buffer for SDS-PAGE to generate a Triton-soluble fraction. An equivalent volume of PHEM buffer and 6x sample buffer was added to the dish, and this sample was added to the pellet from the spin to create a Triton-insoluble fraction. Equal volumes of Triton-soluble and -insoluble fractions, which contained soluble and polymerized tubulin, respectively (Black et al., 1996), were then analyzed by immunoblotting with anti
-tubulin. Quantitation of scanned immunoreactive bands was performed using ImageJ.
Online supplemental material
Fig. S1 shows dot blots of prefibrillar and fibrillar Aß42 and control proteins. Fig. S2 shows a Western blot of cell lysates from the scrambled siRNA- and tau siRNAtreated hippocampal neurons. Video 1 shows that microtubules disassemble in tau-expressing CV-1 cells exposed to prefibrillar Aß42. Video 2 shows that microtubules disassemble in tau- expressing CV-1 cells exposed to prefibrillar Aß40. Video 3 shows that tau is required for prefibrillar Aß42 to induce microtubule disassembly. Video 4 demonstrates that fibrillar Aß42 does not induce microtubule disassembly in tau-expressing cells. Video 5 shows that prefibrillar Aß42 does not induce microtubule disassembly in MAP2c-expressing cells. Video 6 demonstrates that prefibrillar Aß42 does not induce microtubule disassembly in cells expressing MAP2c chimera. Video 7 shows that prefibrillar Aß42 induces microtubule disassembly in cells expressing tau chimera. Video 8 demonstrates that prefibrillar Aß42 induces microtubule disassembly in cells expressing the N-terminal tau arm. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200605187/DC1.
| Acknowledgments |
|---|
This work is supported by National Institutes of Health grants AG20465 and AG02665 (to M.E. King), NS051746 (to G.S. Bloom), NS312230 (to C.G. Glabe), and NS028785 (to P. Baas); the Virginia Center on Aging grant 06-05 (to M.E. King); University of Virginia Graduate School of Arts and Sciences interim funds (to A. Erisir); Alzheimer's Association grant IIRG-06-26604 (to P. Baas); and Larry L. Hillblom Foundation grant 2001-2-C (to C.G. Glabe).
Submitted: 30 May 2006
Accepted: 18 October 2006
| References |
|---|
|
|
|---|
Bitan, G., M.D. Kirkitadze, A. Lomakin, S.S. Vollers, G.B. Benedek, and D.B. Teplow. 2003. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA. 100:330335.
Black, M.M., T. Slaughter, S. Moshiach, M. Obrocka, and I. Fischer. 1996. Tau is enriched on dynamic microtubules in the distal region of growing axons. J. Neurosci. 16:36013619.
Burdick, D., B. Soreghan, M. Kwon, J. Kosmoski, M. Knauer, A. Henschen, J. Yates, C. Cotman, and C. Glabe. 1992. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 267:546554.
Dehmelt, L., and S. Halpain. 2005. The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 6:204.[CrossRef][Medline]
Fifre, A., I. Sponne, V. Koziel, B. Kriem, F.T. Yen Potin, B.E. Bihain, J.L. Olivier, T. Oster, and T. Pillot. 2006. Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. J. Biol. Chem. 281:229240.
Gotz, J., F. Chen, J. van Dorpe, and R.M. Nitsch. 2001. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 293:14911495.
Guo, J.P., T. Arai, J. Miklossy, and P.L. McGeer. 2006. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 103:19531958.
Hardy, J., and D.J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353356.
Kayed, R., E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:486489.
Khlistunova, I., J. Biernat, Y. Wang, M. Pickhardt, M. von Bergen, Z. Gazova, E. Mandelkow, and E.M. Mandelkow. 2006. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281:12051214.
Lee, V.M., M. Goedert, and J.Q. Trojanowski. 2001. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:11211159.[CrossRef][Medline]
Lesne, S., M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, and K.H. Ashe. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440:352357.[CrossRef][Medline]
Lewis, J., D.W. Dickson, W.L. Lin, L. Chisholm, A. Corral, G. Jones, S.H. Yen, N. Sahara, L. Skipper, D. Yager, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 293:14871491.
Mateer, S.C., A.E. McDaniel, V. Nicolas, G.M. Habermacher, M.-J.S. Lin, D.A. Cromer, M.E. King, and G.S. Bloom. 2002. The mechanism for regulation of the F-actin binding activity of IQGAP1 by calcium/calmodulin. J. Biol. Chem. 277:1232412333.
Oddo, S., A. Caccamo, L. Tran, M.P. Lambert, C.G. Glabe, W.L. Klein, and F.M. Laferla. 2006. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease: a link between Abeta and tau pathology. J. Biol. Chem. 281:15991604.
Qiang, L., W. Yu, A. Andreadis, M. Luo, and P.W. Baas. 2006. Tau protects microtubules in the axon from severing by katanin. J. Neurosci. 26:31203129.
Rapoport, M., H.N. Dawson, L.I. Binder, M.P. Vitek, and A. Ferreira. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA. 99:63646369.
Roger, B., J. Al-Bassam, L. Dehmelt, R.A. Milligan, and S. Halpain. 2004. MAP2c, but not tau, binds and bundles F-actin via its microtubule binding domain. Curr. Biol. 14:363371.[CrossRef][Medline]
Selkoe, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741766.
Shen, S.S., W.C. Tucker, E.R. Chapman, and R.A. Steinhardt. 2005. Molecular regulation of membrane resealing in 3T3 fibroblasts. J. Biol. Chem. 280:16521660.
Sponne, I., A. Fifre, B. Drouet, C. Klein, V. Koziel, M. Pincon-Raymond, J.L. Olivier, J. Chambaz, and T. Pillot. 2003. Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem. 278:34373445.
Tanzi, R.E. 2005. Tangles and neurodegenerative diseasea surprising twist. N. Engl. J. Med. 353:18531855.
Walsh, D.M., I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, and D.J. Selkoe. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535539.[CrossRef][Medline]
Wisco, D., E.D. Anderson, M.C. Chang, C. Norden, T. Boiko, H. Folsch, and B. Winckler. 2003. Uncovering multiple axonal targeting pathways in hippocampal neurons. J. Cell Biol. 162:13171328.
Related Article
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|